BC049349 Activators
BC049349 activators are chemicals designed to increase the function of the BC049349 protein. Discovery of these activators typically begins with an extensive high-throughput screening (HTS) process. This process involves systematically testing a vast library of compounds to identify those capable of upregulating BC049349 activity. The assays used in HTS are meticulously crafted to provide quantitative feedback, often utilizing changes in signals such as fluorescence or luminescence that correlate with the activation of the BC049349 protein. Compounds that are observed to elevate the activity of BC049349 are singled out for subsequent analysis. Confirmatory secondary assays are then employed to further investigate these initial hits. These assays are more targeted and refined, designed to validate the activator's effect on BC049349 while eliminating any compounds that produce false positive results due to nonspecific interactions.
Once the initial suite of BC049349 activators is identified and confirmed, the focus shifts to an in-depth analysis of their interaction with the BC049349 protein. Advanced structural biology techniques, including X-ray crystallography or cryo-electron microscopy, are used to visualize how these activators bind to and affect BC049349. This structural insight is pivotal for understanding the underlying mechanisms through which these compounds enhance BC049349 activity. Simultaneously, biophysical methods such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) provide quantitative data on the kinetics and strength of the interaction between BC049349 and its activators. This data is instrumental in understanding the binding efficiency and duration of the activator's effect. Furthermore, structure-activity relationship (SAR) studies systematically modify the chemical structure of the activators to determine which alterations increase the efficacy of BC049349 activation. These studies are vital for pinpointing the chemical moieties essential for the interaction and can lead to the refinement of activator compounds, optimizing their ability to interact with and activate BC049349.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents cAMP breakdown, thus potentiating the signaling pathways that rely on cAMP, possibly leading to an increase in BC049349 activity if cAMP signaling is involved. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), which can phosphorylate a variety of proteins. If BC049349 is a substrate for PKC or is regulated by PKC signaling, PMA could enhance its activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentrations, potentially activating calcium-dependent protein kinases that may phosphorylate and activate BC049349. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine is a substrate for nitric oxide synthase and can increase the production of nitric oxide, which may activate soluble guanylate cyclase and increase cGMP levels, possibly enhancing BC049349 activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits certain types of kinases and could modulate signaling pathways upstream of BC049349, potentially leading to its enhanced activity if those pathways are inhibitory to BC049349. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, particularly PDE5, leading to increased cGMP levels, which may enhance the activity of BC049349 if it is regulated by cGMP-dependent pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor; by inhibiting PI3K, this compound could alter the downstream signaling, including AKT pathway, potentially leading to the activation of BC049349 if it is regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which could shift the balance of MAPK signaling away from the ERK pathway, potentially leading to the activation of BC049349 if it is regulated by these pathways. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A, which could lead to enhanced phosphorylation levels of proteins, including a potential increase in BC049349 activity if it is regulated by phosphorylation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate stress-activated protein kinases (SAPKs/JNKs); if BC049349 is a target of these kinases or is involved in the response to stress signals, anisomycin could enhance its activity. | ||||||